Baird Downgrades Voyager Therapeutics (VYGR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts VYGR Hot Sheet
Price: $1.83 +2.81%
Rating Summary:
17 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 12
Rating Summary:
17 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 12
Join SI Premium – FREE
Baird analyst Brian Skorney downgraded Voyager Therapeutics (NASDAQ: VYGR) from Outperform to Neutral with a price target of $6.00.
For an analyst ratings summary and ratings history on Voyager Therapeutics click here. For more ratings news on Voyager Therapeutics click here.
Shares of Voyager Therapeutics closed at $6.23 yesterday.
You May Also Be Interested In
- Rosenblatt cuts Roku to Neutral as Fox merger nears closing
- Raymond James Downgrades D.R. Horton (DHI) to Underperform
- ICICI Securities Downgrades Syrma SGS Technology (SYRMA:IN) to Add (2)
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
